NWPF

News ArchivesRead News

Schwarz Pharma’s Parkinson’s disease patch receives green light recommendation

Wednesday November 22, 2006

11.17.2006(Forbes) - Schwarz Pharma AG said it has received a recommendation to extend the marketing authorisation of its Neupro patch to treat Parkinson’s disease from the European Committee for Medical Products for Human Use (CHMP).

Upon receipt of approval, Schwarz Pharma will able to market Neupro as a combined therapy for patients with advanced Parkinson’s disease throughout all 25 European countries.

Neupro is already approved and on the European market as a monotherapy treatment for patients with early stage Parkinson’s disease.